Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial-Reference-Cited by-同舟云学术

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial

Published:2013-02 Issue:2 Volume:63 Page:283-295
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Khullar Vik,Amarenco Gerard,Angulo Javier C.,Cambronero Javier,Høye Kjetil,Milsom Ian,Radziszewski Piotr,Rechberger Tomasz,Boerrigter Peter,Drogendijk Ted,Wooning Marianne,Chapple Christopher

Publisher

Elsevier BV

Subject

Urology

Reference16 articles.

1. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction;Irwin;BJU Int,2011

2. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study;Irwin;Eur Urol,2006

3. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study;Coyne;BJU Int,2009

4. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis;Chapple;Eur Urol,2008

5. Clinical guidelines for overactive bladder;Yamaguchi;Int J Urol,2009

Cited by 384 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2024 Revised Dutch guidelines for urinary incontinence: Addressing clinical bottlenecks through a modular approach;Continence;2024-12

2. The history of the pharmacologic treatment of urgency incontinence;Continence Reports;2024-09

3. Mirabegron 50 mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials;Frontiers in Surgery;2024-08-26

4. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder;Neurourology and Urodynamics;2024-07-15

5. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder;Journal of Urology;2024-07